Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by garygpon Nov 22, 2007 3:51pm
247 Views
Post# 13853503

Not meant to be a pump, but....

Not meant to be a pump, but....For some reason(email blast I think), my attention has been drawn to V.MIR, MedMira. There has been an incredible rise in the valuation of this stock and of course the volume over the past week which can be seen in the respective chart. The reason I bring the forgoing to this forum's attention is this. Although MIR is involved in HIV testing, in a recent news release by the company, they, (MIR) specifically attribute the increased interest in their product to the 'CE' marked rapid test kit which enables the test kit to be marketed in Europe. In a recent news release by AMF, reference is specifically made to AMF waiting for our test kits for BSE et al, to be approved for the European market. I'm wondering if we can expect to see an exponential rise in AMF's value should the CE marking be approved for Europe. For disclosure purposes I am a long term holder of AMF stock. garygp
Bullboard Posts